Alkermes PLC
Suletud
SektorTervishoid
50.18 4.32
Ülevaade
Aktsiahinna muutus
24h
Min
47.88
Max
51.57
Sissetulek | -116M -66M |
|---|---|
Müük | 8.4M 393M |
P/E Sektori keskmine | 51.133 50.958 |
Aktsiakasum | 0.38 |
Kasumimarginaal | -16.92 |
Töötajad | 2,050 |
EBITDA | -98M -22M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +4.01% upside |
Järgmine tulemuste avaldamine | 28. juuli 2026 |
|---|
Turukapital | 2B 7.7B |
|---|---|
Eelmine avamishind | 45.86 |
Eelmine sulgemishind | 50.18 |
Uudiste sentiment
By Acuity
10%
90%
13 / 342 Pingereas Healthcare
Alkermes PLC Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
